Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series

Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor used for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Clinical and operational barriers may exist that warrant bridging or switching from thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, David M., Toste, Charina, Nelson, Christopher, Escalon, Juliet, Blevins, Frances, Shah, Bhavesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299792/
https://www.ncbi.nlm.nih.gov/pubmed/34430061
http://dx.doi.org/10.6004/jadpro.2021.12.5.6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299792/
https://www.ncbi.nlm.nih.gov/pubmed/34430061
http://dx.doi.org/10.6004/jadpro.2021.12.5.6

Ejemplares similares